Company description
AC Immune SA (ticker symbol: ACIU) is a Swiss biotechnology company that specializes in the development and discovery of treatments for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Founded in 2003, AC Immune utilizes its proprietary technology platforms to develop novel therapeutic and diagnostic products for the early detection and treatment of these devastating diseases. The company has a diverse pipeline of potential treatments, with multiple candidates in various stages of clinical development. AC Immune's approach focuses on targeting misfolded proteins, which are considered to be a key driver in the progression of Alzheimer's and Parkinson's. With a team of experienced scientists and partnerships with renowned academic institutions and pharmaceutical companies, AC Immune is making strides in the fight against neurodegenerative diseases. In addition to its therapeutic programs, the company also has a strong focus on developing accurate and non-invasive diagnostics to aid in the early detection and monitoring of these diseases. AC Immune is dedicated to bringing innovative solutions to patients and families affected by neurodegenerative diseases, and is well-positioned to continue its growth and success in the field.